Cosmos Health: A Company Transformed — 2026 Year-to-Date
Cosmos Health outlines rapid revenue growth, deleveraging, brand expansion and IP progress in a detailed year-to-date 2026 corporate update.
Rhea-AI Summary
Cosmos Health (COSM) reported three consecutive record revenue periods through H1 2026, while deleveraging its balance sheet and streamlining its capital structure.
Revenue rose to $65.27M in FY2025 (+20% YoY), then to $17.93M in Q1 2026 (+30.7%) and $18.99M in Q2 2026 (+28.8%), for H1 2026 revenue of $36.91M (+29.7%). Adjusted gross profit grew 83% in 2025 to $7.9M, and H1 2026 adjusted gross profit increased 58% YoY. Total liabilities fell to $40.79M, down 13.3% from year-end 2025, while stockholders’ equity rose 12.2% to $20.67M.
The company fully repaid an $8.0M ATW convertible note 12 months early, withdrew shelf registrations, allowed 4.87M Series B warrants to expire, and repurchased 5.1M+ shares for about $1.11M under a $5M authorization. Management highlighted non-core assets of about $20M, a growing digital asset and real estate portfolio, new IP such as the CCX0722 hydrogel patent filings, UK retail wins for C‑Scrub, Gulf-region distribution deals for Sky Premium Life, and reaffirmed 2026 revenue guidance of $90M+ and 2029 targets of $200.6M revenue and $31.0M net income.
Positive
- Revenue $36.91M in H1 2026, up 29.7% year over year
- FY2025 revenue $65.27M, +20% YoY with gross profit +83% to $7.9M
- Total liabilities cut by $6.27M (−13.3%) to $40.79M by June 30, 2026
- Stockholders’ equity increased by $2.25M (+12.2%) to $20.67M
- $8.0M ATW convertible note repaid 12 months early, removing dilution overhang
- 5.1M+ shares repurchased for about $1.11M under a $5M buyback program
Negative
- H1 2026 adjusted EBITDA remained negative at −$1.13M despite revenue growth
- The company still carries $40.79M in total liabilities as of June 30, 2026
News Explained
The EIB arrangement could provide up to €25 million, but the disclosure describes advisory-stage potential rather than committed financing.
Cosmos Health reports a May 2026 advisory agreement for a
As of
The material milestone is whether the advisory process produces an EIB financing commitment for the R&D program and on what terms.
Sources and calculations
- Cosmos Health 2026 year-to-date corporate update (2026-09-03)
- Cosmos Health Q2 2026 fundamentals (2026-06-30)
- Available liquidity against the last reported quarterly operating outflow, in days at that rate ($1,800,949 + $37,464) / ($1,718,254 / 91) = 97.4 days
Market Reaction – COSM
Following this news, COSM has gained 2.63%, reflecting a moderate positive market reaction. Our momentum scanner has triggered 7 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $0.23. Trading volume is above average at 1.6x the average, suggesting increased trading activity.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 28 | Balance sheet update | Positive | +3.9% | Convertible note retirement and reported liability reduction removed stated dilution mechanisms. |
| Aug 24 | Product revenue projection | Positive | -6.7% | Oliv18 projected incremental U.S. revenue and gross profit within 12–18 months. |
| Aug 20 | Saudi distribution agreement | Positive | +10.2% | Exclusive Innova agreement included 126,000-unit initial order and five-year volume expectations. |
| Aug 19 | Q2 earnings report | Neutral | -6.6% | Revenue and liabilities improved while quarterly net loss widened and adjusted EBITDA remained negative. |
| Jul 27 | Subscription platform update | Positive | +3.8% | AI-enabled subscription platform development followed NOOR Collagen repeat purchases above 60%. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news reactions were mixed, with three aligned positive responses and two divergent declines following positive or mixed announcements.
Key Terms
convertible note financial
shelf registration financial
atm offering financial
floorless warrants financial
cagr financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Record Revenue Across All Quarters Reported. Balance Sheet Deleveraged. Capital Structure Streamlined. Proprietary IP Filed in Four Global Markets. U.S. Market Entered. Global rollout of proprietary brands continues. Share repurchases underway. Reaffirms Guidance Targets
A Comprehensive Corporate Summary — January 1, 2026 through August 31, 2026
- Revenue record set three consecutive quarters: FY2025
$65.3M (+20% ) → Q1 2026$17.93M (+31% ) → Q2 2026$18.99M (+28.8% ) → H1 2026$36.91M (+29.7% ). Annualized adjusted run-rate exceeds$75M . Full-year 2026 guidance:$90M +. - ATW
$8M convertible note retired 12 months early: No further conversions, no dilution. - Strengthened balance sheet: H1 2026 total liabilities reduced
13.3% and stockholders’ equity increased12.2% - Simplified capital structure: No shelf registration, no ATM, no floorless warrants.
- 5.1M+ shares repurchased for ~
$1.11M under the$5M buyback. - Management increasing ownership: CEO Greg Siokas personally increased ownership by 3.3M+ shares in 2025 and a further 7.8M+ shares in 2026, bringing his total holding to 14.6M shares.
- Zacks Small-Cap Research initiates coverage:
$4.50 price target vs. a share price well below that level. - C-Scrub now in Tesco and Superdrug: placement in the UK's #1 and #2 health/beauty retailers, serving tens of millions of customers weekly; also establishing presence across hospital and surgical channels following EN 12791 certification, and entering the global animal health market.
- Sky Premium Life global rollout: exclusive Saudi Arabia agreement with Innova Healthcare (126K units initial PO, 5M+ units projected over 5-year term), Qatar distribution agreement, third consecutive UAE order, and pan-European availability across all 27 EU Member States.
- CCX0722 hydrogel patent (WO2025108566A1) filed in U.S., Europe, Australia and Canada — four markets inside a global weight-management category valued at
$190.6B in 2025 and projected to reach$562B by 2033, growing at14.2% CAGR. - 18 Series U.S. buildout: Cur18™, Liv18™, Oliv18™ and Fort18™ launched/in production. NOOR Collagen DTC with >
60% repeat rate. Combined projected U.S. revenue$22.7M + at70% + gross margins. $3.1M invested in digital asset portfolio in BTC + ETH. Bitcoin holdings now in a gain position.- ~
$20M in non-core assets identified for potential monetization — including wholly owned real estate and digital assets, without impacting core operations. - Operating cash requirements reduced by more than
30% , reflecting revenue growth, operating efficiencies and cost reduction initiatives - 2029 guidance reaffirmed:
$200.6M revenue — a32% CAGR from FY2025 — alongside$71.2M gross profit,$31.0M net income and$44.2M Adj. EBITDA.
CHICAGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ: COSM) today presents a comprehensive corporate update covering all significant operational, financial, and strategic milestones from January 1, 2026 through August 31, 2026.
The Company has executed across every dimension of its stated strategy in 2026: record revenue in every reporting period, a deleveraged and simplified balance sheet, a growing proprietary IP portfolio, meaningful U.S. brand launches, accelerating international expansion, AI-led operational upgrades, and active share repurchases. The update below is structured to give investors a complete view of that transformation.
I. Financial Performance: Three Consecutive Record Periods
Cosmos Health has delivered its highest revenue in Company history across every reporting period in 2026, building on a record FY2025:
FY2025: Revenue
Q1 2026: Revenue
Q2 2026: Revenue
Operating Efficiency: operating cash requirements in H1 2026 ran more than
| METRIC | FY2025 | Q1 2026 | Q2 2026 | H1 2026 | ||
| Revenue | ||||||
| Adj. Gross Profit | + | Expanding | ||||
| Total Liabilities | Improved | − | − | 550bps improvement | ||
| Stockholders’ Equity | Improved | + | + | Consistent growth | ||
| Adj. EBITDA | Improving | − | − | Trend up | ||
II. Strengthened Balance Sheet and Capital Structure
The most consequential financial development of 2026 is the transformation of Cosmos Health’s capital structure. The Company has methodically removed meaningful dilution overhang mechanisms and, as a result, expects its share count to remain broadly stable under its existing capital structure, before accounting for the reduction from ongoing share repurchases.
- Convertible note repaid: On August 28, 2026 the Company repaid in full its
$8.0 million senior secured convertible note issued to ATW in August 2025, together with all accrued interest, twelve months ahead of its August 2027 maturity. The repayment eliminates any further conversions or dilution from that instrument. - Shelf registration withdrawn: The Company has withdrawn its Form S-1 and Form S-3 registration statements. No effective shelf registration or ATM offering program is in place.
- No structured or floorless warrants: Remaining warrants carry fixed exercise prices with no reset or ratchet provisions. In May 2026, 4,874,126 Series B warrants expired unexercised with no new shares issued, removing approximately
38% of the total warrant overhang. The next tranche of warrants carries an exercise price of$0.95 per share, significantly above the current share price. - Share repurchase program: 5,112,000 shares have been repurchased for approximately
$1.11 million under the$5.0 million authorization, with open market purchases ongoing. - Non-core assets: ~
$20M in non-core assets identified for potential monetization (real estate, digital assets, marketable securities), including$15M in real estate at fair market value and$3.1M invested in digital assets (BTC + ETH). Bitcoin holdings are currently in a gain position.
| DECEMBER 31, 2025 | JUNE 30, 2026 | CHANGE | |||
| Total liabilities | − | ||||
| Stockholders’ equity | + | ||||
| Liabilities-to-assets ratio | 550 basis points improvement | ||||
III. Diversified Asset Base and Digital Assets Strategy
The Company maintains a diversified asset base spanning liquid assets, digital holdings and real estate, alongside access to non-dilutive financing. Together these provide flexibility to fund the Company’s next phase of growth without recourse to equity issuance. As previously stated, the Company has identified approximately
Digital Assets
Cosmos Health has built a disciplined digital asset program as a component of its treasury strategy, with initial focus on Ethereum and strategic expansion into Bitcoin:
- February 2026:
$500 K Bitcoin purchase — total investments in digital holdings reach$2.5M - March 2026:
$600 K Bitcoin purchase — total investments in digital holdings reach$3.1M - August 2026: Bitcoin holdings in a gain position as of the date of this release, available for opportunistic monetization
Real Estate
Beyond its liquid and digital assets, Cosmos Health owns a valuable real estate portfolio, with an independent fair market valuation placing it at approximately
European Investment Bank financing
In May 2026, Cana Laboratories entered into an advisory agreement with the European Investment Bank (EIB) for the financing of a
IV. Analyst Coverage and Valuation
On January 14, 2026, Zacks Small-Cap Research initiated analyst coverage of Cosmos Health with a
V. Divisional Performance Snapshot
| DIVISION | 2026 KPI | KEY MILESTONES |
| CosmoFarm | > | Record Q2; |
| Cana Laboratories | 25M+ unit orderbook | All-time high contract manufacturing backlog; multi-year agreements up to 10 years. > |
| Decahedron (UK) | Near 2× revenue | Nearly doubled revenue YoY in Q2 2026. Key distribution hub for UK/European markets with continued growth momentum. |
| 18 Series / NOOR | Cur18™, Liv18™, Oliv18™ and Fort18™ launched or in production. NOOR Collagen > | |
| Sky Premium Life | 5M+ units / Saudi | Saudi Arabia: exclusive 5-year deal with Innova Healthcare (126K initial PO, 5M+ units projected). Qatar: agreement with International Medical Company (31K initial order). UAE: third consecutive Pharmalink order (60K units, 270K cumulative). EU: all 27 Member States via Skroutz. Albania (54K+ annual units), UK and expanding. |
| C-Scrub / C-Sept | UK + hospital + animal health | C-Scrub live at Tesco (#1 UK retailer, ~ |
| CCX0722 Hydrogel | 4 patent markets | WO2025108566A1 advanced into US, EU, Australia & Canada. Mechanical satiety platform — swells more than 100-fold in the stomach with no systemic absorption. Market: |
VI. UK Retail Breakthrough, New Channels and Growth Initiatives
In February 2026, Cosmos Health achieved a landmark dual placement for C-Scrub in the United Kingdom — securing listings with two of the largest retailers in the country:
- Tesco: The UK’s largest retailer, holding ~
30% market share and generating over$80B in annual revenue globally. Tens of millions of customers served weekly. - Superdrug: The UK’s second-largest beauty and health retailer, operating 830+ stores including 200+ in-store pharmacies across the UK and Republic of Ireland, plus a strong e-commerce platform.
The listing in both retailers represents a step-change in C-Scrub’s UK visibility and credibility, and establishes a platform for potential rollout of additional Cosmos Health products. The Company has since extended the franchise into two additional channels:
- Hospital and surgical (April 2026): C-Scrub Wash
4% completed testing under EN 12791, the European standard for surgical hand disinfection, supporting entry into hospital, surgical and professional healthcare procurement channels. C-Sept PRO has since gained traction across leading Greek public and private hospital groups. - EU expansion: C-Scrub and C-Sept reported annualized sales above
$1.5 million at gross margins over70% , with planned European expansion targeting$2.5 million in revenue in 2026, rising to$7.4 million in revenue and$5.3 million in gross profit by 2028. - Animal health (June 2026): Veterinary C-Scrub Wash
4% certified under EN 1656 and EN 1657 European standards — opening the$69B global animal health market. The veterinary line extends an existing certified formulation manufactured in-house at Cana’s facility.
Acquisitions
The Company is actively exploring acquisitions that could be immediately accretive and accelerate progress toward its stated guidance targets. Two letters of intent (LOI) have been signed to date:
- Pharmacy distribution network (March 2026): LOI signed to acquire a
$11.5M pharmacy distribution network, further expanding CosmoFarm’s reach. - Doc Pharma S.A. (June 2026): LOI signed to acquire Doc Pharma S.A., an affiliated European GMP pharmaceutical manufacturer, expected to expand assets, production capacity, product portfolio and profitability.
VII. International Expansion: Saudi Arabia, Dubai, and Global Markets
Cosmos Health accelerated the international rollout of its proprietary brands during 2026, adding exclusive and long-term distribution partnerships across the Gulf while achieving full European coverage for Sky Premium Life. Each agreement is with an established distributor holding significant retail reach in its market.
Saudi Arabia (August 2026): Cosmos Health entered the Kingdom of Saudi Arabia through an exclusive five-year distribution agreement with Innova Healthcare, one of the Kingdom’s largest retail pharmacy networks, operating more than 250 pharmacies with a stated plan to exceed 500. The agreement covers the full Sky Premium Life range. An initial purchase order of 126,000 units was secured on execution, with total expected volume exceeding 5 million units over the initial five-year term. Innova holds a first right of refusal on new Cosmos Health products developed or acquired during the term.
Qatar (June 2026): The Company signed a distribution agreement with International Medical Company, whose Kulud Pharmacies retail arm is the country’s largest chain with more than 130 branches, securing an initial order of 31,000 Sky Premium Life units.
United Arab Emirates (April 2026): A third consecutive purchase order was received from Pharmalink for 60,000 Sky Premium Life units, taking cumulative orders to 270,000 units against a five-year goal of over 3 million units.
European Union (June 2026): Pan-European distribution was achieved for Sky Premium Life through the e-commerce platform Skroutz, making 96 products available for shipment across all 27 EU Member States.
Albania (July 2026): Pharma Cell partnership scaled to 4,500+ monthly units, with annualized orders projected to exceed 54,000 units. Products are distributed across Albania and recommended by healthcare professionals.
Dubai (February 2026): Cosmos Health showcased its expanding brand portfolio at the World Health Expo Dubai 2026, reinforcing the Company’s presence in the Middle East and MENA region.
VIII. CCX0722 Hydrogel: International Patent in Four Markets
On June 25, 2026, Cana Laboratories advanced international patent application WO2025108566A1, “Hydrogel for Body Weight Management,” into the European regional phase and national phases in the United States, Australia and Canada. The IP was acquired outright from Cloudpharm on June 8, 2026 — no licensing fees, no royalty-sharing, no third-party dependency.
CCX0722 works through a simple, mechanical mechanism with no systemic absorption. Taken as a capsule before meals, the dried hydrogel absorbs water in the stomach and swells more than 100-fold into soft gel pieces that occupy stomach volume to support satiety, before naturally passing through the GI tract. The global weight management market was
IX. U.S. Proprietary Brand Buildout: The 18 Series Platform
The 18 Series is Cosmos Health’s portfolio of science-validated nutraceutical products, manufactured in the United States at facilities holding GMP certification and FDA registration. The following products are now in active U.S. commercial launch or production:
- Cur18™ — Patented, clinically studied curcumin formulation delivering up to 39× higher free curcumin bioavailability versus standard
95% curcuminoid extracts. U.S. commercial launch Q2 2026. - Liv18™ — Clinically validated liver health supplement. Phase 1 complete; production commenced April 2026 at a GMP-certified, FDA-registered, UL-audited U.S. facility. Projected
$5M + annual revenue at ~75% gross margin. Tariff-mitigated via U.S.-based manufacturing. - Oliv18™ — Whole olive polyphenol; USDA and EU organic certified;
100% solvent-free. Targeting U.S. cardiovascular and antioxidant categories. Projected$6M + annual revenue at ~72% gross margin within 12–18 months. - Fort18™ — Men’s wellness supplement introduced May 2026. Projected
$3.2M + incremental annual U.S. revenue within 12–18 months. - NOOR Collagen — Korean-developed premium collagen. Subscription model launched with >
60% early repeat purchase rate at >50% gross margins. Projected$12M + annualized revenue. Entering$163B global skincare market.
Combined, the 18 Series / NOOR U.S. portfolio projects over
X. AI Strategy and Operational Infrastructure
AI has moved from strategy to execution at Cosmos Health in 2026, with deployments across commercial, logistics and research functions:
- Enterprise integration (April 2026): AI deployed across front-end order and customer management, back-end warehouse, inventory and supply chain operations, and the proprietary Cloudscreen drug repurposing platform — with the potential to reduce certain operating expenses by up to
30% . - CosmoFarm automation: AI robotic automation deployed for inventory management and order fulfillment, alongside expanded facility capacity supporting an additional
$40M + in annual revenue capacity. - Customer operations (June 2026): AI-powered call center agreement signed — multilingual voice, outbound campaigns and real-time reporting — to optimize order intake and customer communications.
- Subscription platform (July 2026): The Company is actively developing an AI-enabled digital subscription platform spanning consumer (B2C) and corporate (B2B) channels, building on the U.S. subscription launch of NOOR Collagen, which has delivered an early repeat purchase rate above
60% .
These investments underpin the operating leverage the Company expects to demonstrate as revenue scales toward
XI. 2026–2029 Financial Guidance Reaffirmed
The Company reaffirms its guidance issued May 26, 2026. H1 2026 performance is consistent with the trajectory required to achieve these targets:
| METRIC | FY2025 (actual) | 2026 (guidance) | 2027 (guidance) | 2029 (guidance) |
| Revenue | > | |||
| Gross Profit | Expanding | |||
| Net Income | Loss | Near B/E path | ||
| Adj. EBITDA | Improving | Improving | ||
| Cash | Stable+ | |||
The
Management believes that achieving these targets would create significant value for shareholders, as the Company transitions to a self-funded model driven by strong cash flows.
XII. Complete 2026 Milestone Timeline
| DATE | MILESTONE |
| Jan 14 | Zacks Small-Cap Research initiates analyst coverage with |
| Jan 20 | Accelerating CosmoFarm customer growth; robotic expansion supporting |
| Feb 11 | |
| Feb 17 | Cosmos Health showcases expanding brand portfolio at World Health Expo Dubai 2026 |
| Feb 18 | C-Scrub listed at Tesco, the UK’s largest retailer (~ |
| Feb 18 | C-Scrub listed at Superdrug, the UK’s 2nd-largest beauty & health retailer (830+ stores) |
| Feb 19 | Company highlights |
| Mar 10 | |
| Mar 11 | LOI signed to acquire |
| Mar 19 | Corporate update: NOOR Collagen projected at |
| Apr 1 | C-Scrub Wash |
| Apr 8 | Planned U.S. launch of Liv18™ announced |
| Apr 13 | Third consecutive Pharmalink purchase order — 60,000 Sky Premium Life units for the UAE |
| Apr 15 | FY2025 results: Record |
| Apr 16 | Enterprise AI integration announced — potential to reduce certain operating expenses by up to |
| Apr 17 | Cur18™ U.S. commercial launch announced for Q2 2026 |
| Apr 20 | Liv18™ Phase 1 complete; production commencing at GMP/FDA-registered U.S. facility — |
| Apr 30 | Cur18™ projected to contribute |
| May 6 | Fort18™ introduced, extending the 18 Series into men’s wellness |
| May 11 | Fort18™ projected to contribute |
| May 12 | Registration Statement on Form S-1 withdrawn |
| May 14 | Advisory agreement signed with the European Investment Bank for a |
| May 21 | Q1 2026 results: Record |
| May 21 | 4,874,126 Series B warrants expire unexercised — |
| May 26 | 2026–2029 financial guidance: |
| Jun 1 | Veterinary C-Scrub Wash |
| Jun 4 | Pan-European distribution achieved for Sky Premium Life across all 27 EU Member States via Skroutz |
| Jun 4 | |
| Jun 5 | Oliv18™ launched in the United States |
| Jun 8 | Cana Laboratories acquires CCX0722 patent application from Cloudpharm — full IP ownership consolidated |
| Jun 9 | New capsule production line inaugurated; five-year Provident agreement for 385,000 units of CERTORUN |
| Jun 10 | Three-year, 3.9M-unit contract manufacturing agreement signed with Verisfield |
| Jun 11 | LOI signed to acquire Doc Pharma S.A., an affiliated European GMP pharmaceutical manufacturer |
| Jun 12 | C-Scrub and C-Sept annualized sales exceed |
| Jun 12 | Contract manufacturing orders totaling 253,657 units received from Nassington and Verisfield |
| Jun 15 | U.S. portfolio update: four 18 Series products with |
| Jun 17 | Pharmex S.A. contract manufacturing agreement: 2.86M units across three dermatological products |
| Jun 17 | Entry into the |
| Jun 18 | CosmoFarm delivers record Q2 > |
| Jun 22 | Cana orderbook hits all-time high of 25M+ units; > |
| Jun 23 | AI-powered call center agreement signed for CosmoFarm customer communications |
| Jun 24 | C-Sept PRO gains traction across Greek hospital groups — |
| Jun 25 | International patent application WO2025108566A1 advanced into US, EU, Australia and Canada |
| Jun 26 | Distribution agreement signed with International Medical Company for Qatar — 31,000-unit initial order |
| Jun 30 | Board authorizes |
| Jul 7 | Preliminary Q2 record revenue ~ |
| Jul 10 | Subscription model launched with NOOR Collagen — > |
| Jul 13 | Agreement signed with Libytec to commercialize DIABIT-IS X in Greece |
| Jul 17 | Buyback reaches 5.11M shares repurchased for ~ |
| Jul 20 | Albania expansion: Pharma Cell partnership scaled to 4,500+ monthly units, 54K+ annually |
| Jul 27 | AI-enabled digital subscription platform announced across B2C and B2B channels |
| Aug 19 | Q2 2026 results confirmed: |
| Aug 20 | Saudi Arabia entry: exclusive 5-year deal with Innova Healthcare; 126K initial PO; 5M+ units projected |
| Aug 24 | Oliv18™ projected to generate |
| Aug 28 | |
Management Commentary
Greg Siokas, CEO of Cosmos Health, stated: “This is a different company than it was twelve months ago. We have retired
“Every pillar of our strategy is delivering. CosmoFarm is growing its pharmacy network and deploying AI. Cana has its biggest contract manufacturing orderbook in history. Decahedron nearly doubled its UK revenue. Our proprietary brands are gaining real commercial traction.
“We enter the second half of 2026 with a solid balance sheet and a streamlined capital structure, growing revenue across every division, and a clear path to
About Cosmos Health Inc.
Cosmos Health Inc. (NASDAQ: COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b3c3061f-2b75-4eaf-9ca4-2e98bdd664b2
